Kharitonov 1996.
Methods | Setting: UK, hospital outpatient clinic Randomisation: yes, method not stated Allocation concealment: unclear Design: crossover, 3 week washout Intervention period: 3 weeks Masking: double blind Excluded: not stated Withdrawals: not stated Baseline characteristics: comparable Jadad score=2 | |
Participants | 11 adults: 8M 3F Age range: 26‐36 years Inclusion criteria: Atopic asthma Positive skin prick test to at least 2 allergens FEV1 (% predicted) >70 Methacholine BHR (PC20 FEV1) < 8 mg/ml Exclusion criteria: Regular oral or inhaled steroid use Respiratory tract infection or asthma exacerbation in last month | |
Interventions | BUD: 800 mcg 2xdaily (1600 mcg/d) Placebo: 2xdaily Delivery device: Turbohaler DPI |
|
Outcomes | FEV1 (% predicted) Methacholine BHR (PC20 FEV1) Exhaled air nitric oxide concentration | |
Notes | No reply from author to clarify details of randomisation method. | |
Risk of bias | ||
Bias | Authors' judgement | Support for judgement |
Allocation concealment? | Unclear risk | B ‐ Unclear |